reference/20380385

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20380385

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	1156
issn	1078-0432 1557-3265
issueIdentifier	6
pageRange	1147-1156
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	1147
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_963c5093529222a0806502f6baa3878a
bibliographicCitation	Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Zhao X, Wang D, Zhang P, Wang Y, Wang L, Liu T, Zhang Y, Shen Z, Huang J, Zhu J. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis. Clin Cancer Res. 2022 Mar 15;28(6):1147–56. PMID: 34716199; PMCID: PMC9365351.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4fb0d00b5c5034a06d2872e93cbe27b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1332-9230 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c20dcf14b048320ea11bbbf980cb4b7e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16c7189c5e22e9db2dc255969a250257 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_772e6695d6967d6e651946cdc60cc854 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5982b84301637d7349b63fe4d3131257 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39de5ad2bcd86ef53584a4bcb216f515 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-2751-7160 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b888418c3a3e793fd8f49f4d39223006 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca9cab1cfcd46c2c88e20001b6323190 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce9926045c2d0ba0baf044212e5489b2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7736ec0a74b47e1be91f83ea7b38edb3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb9a73bfda9ec1918edf52ca2fbc653b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e2f32ba4669f823005b42b057d4342b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_06c26556773bd11f188ccfa6875de7a3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9aacb9e90e470087b8d9d2dc03a70945 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83d70bdc498d8372c9a7e1bae2dab253 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f59ad594d1d34a5a3200eddba2d68a73 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7d561b0aa1ccdcbba274be336c30389 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_881a0dbb2dead187da6521cda273f049 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9137fe389d3788dfc8786b5f58f9a09a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a665621427b3498f7bc8d7ce89cf902 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_82c8a142bfd115ada04618237d2ee99d
date	2022-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC9365351 https://pubmed.ncbi.nlm.nih.gov/34716199 https://doi.org/10.1158/1078-0432.ccr-21-2023
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794 https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
discusses	http://id.nlm.nih.gov/mesh/M000734928 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0001357
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D018380 http://id.nlm.nih.gov/mesh/D006689
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D014182 http://id.nlm.nih.gov/mesh/D000911Q000009 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D009364Q000188 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D009364Q000473
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b83d04d3e3b05ce10d1a5893dc850a9b http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8035

Total number of triples: 58.